Anp-npra signaling pathway-a potential therapeutic target for the treatment of malignancy

Critical Reviews in Eukaryotic Gene Expression

Volumn 23, Issue 2, 2013, Pages 93-101

  Zhao, Zhilong ^a   Zhang, Jia ^a   Li, Min ^a   Yang, Ya ^a   Sun, Kai ^a   Wang, Jiansheng ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

ANP; Cancer; NPRA; Target; Treatment

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; DEXAMETHASONE; MITOGEN ACTIVATED PROTEIN KINASE 1; NATRIURETIC PEPTIDE RECEPTOR A; PLATELET DERIVED GROWTH FACTOR RECEPTOR; VASCULOTROPIN;

ACIDIFICATION; AMINO ACID SEQUENCE; APOPTOSIS; CARCINOGENESIS; CELL MEMBRANE; CELL PROLIFERATION; DEGLYCOSYLATION; DIMERIZATION; DISULFIDE BOND; DOWN REGULATION; ENZYME ACTIVE SITE; GENE EXPRESSION; HUMAN; LUNG SMALL CELL CANCER; NONHUMAN; OVARY CANCER; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; STOMACH CANCER; THYROID MEDULLARY CARCINOMA; TUMOR VOLUME;

AMINO ACID SEQUENCE; ANIMALS; ATRIAL NATRIURETIC FACTOR; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROSTATIC NEOPLASMS; RECEPTORS, ATRIAL NATRIURETIC FACTOR; SIGNAL TRANSDUCTION;

MUS;

EID: 84875884636     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukarGeneExpr.2013006641     Document Type: Review

References (67)

1. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats (reprinted from Life Sci, 1981;28:89-94). J Am Soc Nephrol. 2001;12(2):403-407.
2. Currie MG, Geller DM, Cole BR, Boylan JG, Wu YS, Holmberg SW, Needleman P. Bioactive cardiac substances-potent vasorelaxant activity in mammalian atria. Science. 1983;221(4605):71-3.
3. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature. 1988;332(6159):78-81.
4. Fiscus RR. Involvement of cyclic GMP and protein kinase G in the regulation of apoptosis and survival in neural cells. Neurosignals. 2002;11(4):175-90.
5. Pedram A, Razandi M, Kehrl J, Levin ER. Natriuretic peptides inhibit G protein activation. Mediation through cross-talk between cyclic GMP-dependent protein kinase and regulators of G protein-signaling proteins. J Biol Chem. 2000;275(10):7365-72.
6. Silberbach M, Roberts CT Jr. Natriuretic peptide signalling: Molecular and cellular pathways to growth regulation. Cell Signal. 2001;13(4):221-31.
7. Wang X, Raulji P, Mohapatra S., Patel R, Hellermann G, Kong X, Vera PL, Meyer-Siegler KL, Coppola D, Mohapatra S. Natriuretic peptide receptor a as a novel target for prostate cancer. Mol Cancer. 2011;10:56.
8. Ding JH, Chang YS. Atrial natriuretic peptide: A possible mediator involved in dexamethasone's inhibition of cell proliferation in multiple myeloma. Med Hypotheses. 2012;79(2):207-9.
9. Kong X, Wang X, Xu W, Behera S, Hellermann G, Kumar A, Lockey RF, Mohapatra S, Mohapatra SS. Natriuretic peptide receptor A as a novel anticancer target. Cancer Res. 2008;68(1):249-56.
10. Debold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981;28(1):89-94.
11. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP)-A new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun. 1990;168(2):863-70.
12. McGrath MF, de Bold AJ. Determinants of natriuretic peptide gene expression. Peptides. 2005;26(6):933-43.
13. Yan W, Wu F, Morser J, Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci U S A. 2000;97(15):8525-9.
14. Wu F, Wu Q. Corin-mediated processing of pro-atrial natriuretic peptide in human small cell lung cancer cells. Cancer Res. 2003;63(23):8318-22.
15. Cameron VA, Aitken GD, Ellmers LJ, Kennedy MA, Espiner EA. The sites of gene expression of atrial, brain, and C-type natriuretic peptides in mouse fetal development: temporal changes in embryos and placenta. Endocrinology. 1996;137(3):817-24.
16. Brenner BM, Ballermann BJ, Gunning ME, Zeidel ML. Diverse biological actions of atrial natriuretic peptide. Physiol Rev. 1990;70(3):665-99.
17. Ishigaki N, Yamamoto N, Jin H, Uchida K, Terai S, Sakaida I. Continuos intravenous infusion of atrial natriuretic peptide (ANP) prevented liver fibrosis in rat. Biochem Biophys Res Commun. 2009;378(3):354-9.
18. Nigwekar SU, Navaneethan SD, Parikh CR, Hix JK. Atrial natriuretic peptide for management of acute kidney injury: A systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4(2):261-72.
19. Vollmar AM. The role of atrial natriuretic peptide in the immune system. Peptides. 2005;26(6):1086-94.
20. Luft FC, Lang RE, Aronoff GR, Ruskoaho H, Toth M, Ganten D, Sterzel RB, Unger T. Atriopeptin-III kinetics and pharmacodynamics in normal and anephric rats. J Pharmacol Exp Ther. 1986;236(2):416-8.
21. Chinkers M, Garbers DL, Chang MS, Lowe DG, Chin HM, Goeddel DV, Schulz S. A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature. 1989;338(6210):78-83.
22. Schulz S, Singh S, Bellet RA, Singh G, Tubb DJ, Chin H, Garbers DL. The primary structure of a plasma-membrane guanylate-cyclase demonstrates diversity within this new receptor family. Cell. 1989;58(6):1155-62.
23. Chang M, Lowe DG, Lewis M, Hellmiss R, Chen E, Goeddel DV. Differential activation by atrial and brain natriuretic peptides of 2 different receptor guanylate cyclases. Nature. 1989;341(6237):68-72.
24. Pandey KN, Singh S. Molecular-cloning and expression of murine guanylate-cyclase atrial-natriuretic-factor receptor CDNA. J Biol Chem. 1990;265(21):12342-8.
25. Takahashi Y, Nakayama T, Soma M, Izumi Y, Kanmatsuse K. Organization of the human natriuretic peptide receptor A gene. Biochem Biophys Res Commun. 1998;246(3):736-9.
26. Garbers DL. Guanylyl cyclase receptors and their endocrine, paracrine, and autocrine ligands. Cell. 1992;71(1):1-4.
27. Miyagi M, Zhang X, Misono KS. Glycosylation sites in the atrial natriuretic peptide receptor: Oligosaccharide structures are not required for hormone binding. Eur J Biochem. 2000;267(18):5758-68.
28. Koller KJ, Lipari MT, Goeddel DV. Proper glycosylation and phosphorylation of the type A natriuretic peptide receptor are required for hormone-stimulated guanylyl cyclase activity. J Biol Chem. 1993;268(8):5997-6003.
29. Abe T, Nishiyama K, Snajdar R, He X, Misono KS. Aortic smooth muscle contains guanylate-cyclasecoupled 130-kDa atrial natriuretic factor receptor as predominant receptor form. Spontaneous switching to 60-kDa C-receptor upon cell culturing. Eur J Biochem. 1993;217(1):295-304.
30. Ogawa H, Qiu Y, Ogata CM, Misono KS. Crystal structure of hormone-bound atrial natriuretic peptide receptor extracellular domain: rotation mechanism for transmembrane signal transduction. J Biol Chem. 2004;279(27):28625-31.
31. Misono KS, Ogawa H, Qiu Y, Ogata CM. Structural studies of the natriuretic peptide receptor: a novel hormoneinduced rotation mechanism for transmembrane signal transduction. Peptides. 2005;26(6):957-68.
32. Ogawa H, Qiu Y, Huang L, Tam-Chang SW, Young HS, Misono KS. Structure of the atrial natriuretic peptide receptor extracellular domain in the unbound and hormone-bound states by single-particle electron microscopy. FEBS J. 2009;276(5):1347-55.
33. van den Akker F, Zhang X, Miyagi M, Huo X, Misono KS, Yee VC. Structure of the dimerized hormone-binding domain of a guanylyl-cyclase-coupled receptor. Nature. 2000;406(6791):101-4.
34. De Lean A, McNicoll N, Labrecque J. Natriuretic peptide receptor A activation stabilizes a membrane-distal dimer interface. J Biol Chem. 2003;278(13):11159-66.
35. Pandey KN. Biology of natriuretic peptides and their receptors. Peptides. 2005;26(6):901-32.
36. Garbers DL, Chrisman TD, Wiegn P, Katafuchi T, Albanesi JP, Bielinski V, Barylko B, Redfield MM, Burnett JC Jr. Membrane guanylyl cyclase receptors: An update. Trends Endocrinol Metab. 2006;17(6):251-8.
37. Lowe DG, Chang MS, Hellmiss R, Chen E, Singh S, Garbers DL, Goeddel DV. Human atrial natriuretic peptide receptor defines a new paradigm for second messenger signal transduction. EMBO J. 1989;8(5):1377-84.
38. Duda T, Goraczniak RM, Sharma RK. Core sequence of ATP regulatory module in receptor guanylate cyclases. FEBS Lett. 1993;315(2):143-8.
39. Wong SK, Ma CP, Foster DC, Chen AY, Garbers DL. The guanylyl cyclase-A receptor transduces an atrial natriuretic peptide/ATP activation signal in the absence of other proteins. J Biol Chem. 1995;270(51):30818-22.
40. Liu Y, Ruoho AE, Rao VD, Hurley JH. Catalytic mechanism of the adenylyl and guanylyl cyclases: Modeling and mutational analysis. Proc Natl Acad Sci U S A. 1997;94(25):13414-9.
41. Sunahara RK, Beuve A, Tesmer JJ, Sprang SR, Garbers DL, Gilman AG. Exchange of substrate and inhibitor specificities between adenylyl and guanylyl cyclases. J Biol Chem. 1998;273(26):16332-8.
42. Tucker CL, Hurley JH, Miller TR, Hurley JB. Two amino acid substitutions convert a guanylyl cyclase, RetGC-1, into an adenylyl cyclase. Proc Natl Acad Sci U S A. 1998;95(11):5993-7.
43. Winger JA, Derbyshire ER, Lamers MH, Marletta MA, Kuriyan J. The crystal structure of the catalytic domain of a eukaryotic guanylate cyclase. BMC Struct Biol. 2008;8:42.
44. Rauch A, Leipelt M, Russwurm M, Steegborn C. Crystal structure of the guanylyl cyclase Cya2. Proc Natl Acad Sci U S A. 2008;105(41):15720-5.
45. Tesmer JJ, Sunahara RK, Gilman AG, Sprang SR. Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsalpha.GTPgammaS. Science. 1997;278(5345):1907-16.
46. Zhang G, Liu Y, Ruoho AE, Hurley JH. Structure of the adenylyl cyclase catalytic core. Nature. 1997;386(6622):247-53.
47. Tripathi S, Pandey KN. Guanylyl cyclase/natriuretic peptide receptor-A signaling antagonizes the vascular endothelial growth factor-stimulated MAPKs and downstream effectors AP-1 and CREB in mouse mesangial cells. Mol Cell Biochem. 2012;368(1-2):47-59.
48. Xing J, Moldobaeva N, Birukova AA. Atrial natriuretic peptide protects against Staphylococcus aureus-induced lung injury and endothelial barrier dysfunction. J Appl Physiol. 2011;110(1):213-24.
49. Wang DJ, Oparil S, Xing DQ, Shi WB, Cao X, Chen YF. Atrial natriuretic peptide (ANP) inhibits transforming growth factor (TGF)-beta 1-induced nuclear translocation of Smad3 and myofibroblast transformation in mouse cardiac fibroblasts. Circulation. 2005;112(17):U154-U.
50. Ohsaki Y, Yang HK, Le PT, Jensen RT, Johnson BE. Human small cell lung cancer cell lines express functional atrial natriuretic peptide receptors. Cancer Res. 1993;53(13):3165-71.
51. Bliss DP Jr, Battey JF, Linnoila RI, Birrer MJ, Gazdar AF, Johnson BE. Expression of the atrial natriuretic factor gene in small cell lung cancer tumors and tumor cell lines. J Natl Cancer Inst. 1990;82(4):305-10.
52. Gross AJ, Steinberg SM, Reilly JG, Bliss DP Jr, Brennan J, Le PT, Simmons A, Phelps R, Mulshine JL, Ihde DC, Johnson BE. Atrial natriuretic factor and arginine vasopressin production in tumor cell lines from patients with lung cancer and their relationship to serum sodium. Cancer Res. 1993;53(1):67-74.
53. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Alli AA, Solivan SM, Gower WR, Vesely DL. Five cardiac hormones decrease the number of human small-cell lung cancer cells. Eur J Clin Invest. 2005;35(6):388-98.
54. Vesely BA, Alli A, Song S, Sanchez-Ramos J, Fitz SR, Gower WR Jr, Vesely DL. Primary malignant tumors of the heart: Four cardiovascular hormones decrease the number and DNA synthesis of human angiosarcoma cells. Cardiology. 2006;105(4):226-33.
55. Vesely BA, Eichelbaum EJ, Alli AA, Sun Y, Gower WR Jr, Vesely DL. Four cardiac hormones cause cell death of melanoma cells and inhibit their DNA synthesis. Am J Med Sci. 2007;334(5):342-9.
56. Eichelbaum EJ, Vesely BA, Alli AA, Sun Y, Gower WR Jr, Vesely DL. Four cardiac hormones eliminate up to 82% of human medullary thyroid carcinoma cells within 24 hours. Endocrine. 2006;30(3):325-32.
57. Vesely DL. Which of the cardiac natriuretic peptides is most effective for the treatment of congestive heart failure, renal failure and cancer? Clin Exp Pharmacol Physiol. 2006;33(3):169-76.
58. Vesely DL, Eichelbaum EJ, Sun Y, Alli AA, Vesely BA, Luther SL, Gower WR Jr. Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones. In Vivo. 2007;21(3):445-51.
59. Eichelbaum EJ, Sun Y, Alli AA, Gower WR Jr, Vesely DL. Cardiac and kidney hormones cure up to 86% of human small-cell lung cancers in mice. Eur J Clin Invest. 2008;38(8):562-70.
60. Vesely DL, Vesely BA, Eichelbaum EJ, Sun Y, Alli AA, Gower WR Jr. Four cardiac hormones eliminate up to two-thirds of human breast cancers in athymic mice. In Vivo. 2007;21(6):973-8.
61. Vesely BA, McAfee Q, Gower WR Jr, Vesely DL. Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur J Clin Invest. 2003;33(11):998- 1005.
62. Sun Y, Eichelbaum EJ, Lenz A, Wang H, Vesely DL. Epidermal growth factor's activation of Ras is inhibited by four cardiac hormones. Eur J Clin Invest. 2010;40(5):408-13.
63. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Atrial natriuretic peptide and long acting natriuretic peptide inhibit ERK 1/2 in prostate cancer cells. Anticancer Res. 2006;26(6B):4143-8.
64. Baldini PM, De Vito P, Vismara D, Bagni C, Zalfa F, Minieri M, Di Nardo P. Atrial natriuretic peptide effects on intracellular pH changes and ROS production in HEPG2 cells: role of p38 MAPK and phospholipase D. Cell Physiol Biochem. 2005;15(1-4):77-88.
65. Vesely BA, Alli AA, Song SJ, Gower WR Jr, Sanchez-Ramos J, Vesely DL. Four peptide hormones' specific decrease (up to 97%) of human prostate carcinoma cells. Eur J Clin Invest. 2005;35(11):700-10.
66. Martey CA, Pollock SJ, Turner CK, O'Reilly KM, Baglole CJ, Phipps RP, Sime PJ. Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: Implications for lung inflammation and cancer. Am J Physiol Lung Cell Mol Physiol. 2004;287(5):L981-91.
67. Karin M. Mitogen activated protein kinases as targets for development of novel anti-inflammatory drugs. Ann Rheum Dis. 2004;63(Suppl 2):ii62-ii4.